Hos patienter med infektioner, der vides at infiltrere knoglemarven, eller maligne sygdomme bør en passende behandling af den tilgrundliggende sygdom overvejes ud over administration af filgrastim til behandling af neutropeni.
In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia.